Loading clinical trials...
Loading clinical trials...
Efficacy and Safety of Epigallocatechin-3-gallate, an Important Polyphenolic That Originates From Tea, in Patients With Esophageal Squamous Cancer: A Phase II Trial
Conditions
Interventions
Epigallocatechin-3-gallate
Locations
1
China
Shandong Cancer Hospital
Jinan, Shandong, China
Start Date
April 22, 2024
Primary Completion Date
April 22, 2026
Completion Date
May 22, 2026
Last Updated
May 3, 2024
NCT06713993
NCT06257264
NCT00242723
NCT06253871
NCT05005403
NCT04674267
Lead Sponsor
Shandong Cancer Hospital and Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions